(Total Views: 729)
Posted On: 04/12/2021 8:22:22 PM
Post# of 148876
Gilead Sciences said on Monday it had decided to stop a late-stage trial of its intravenous treatment, Veklury, in high-risk non-hospitalized patients with Covid-19.
The company said it no longer believes that developing a multiple-day injection that requires administration in a healthcare setting addresses an unmet need for non-hospitalized patients.
The decision to stop the study is not due to efficacy or safety concerns, Gilead said
https://www.cnbc.com/2021/04/12/gilead-to-sto...tment.html
The company said it no longer believes that developing a multiple-day injection that requires administration in a healthcare setting addresses an unmet need for non-hospitalized patients.
The decision to stop the study is not due to efficacy or safety concerns, Gilead said
https://www.cnbc.com/2021/04/12/gilead-to-sto...tment.html
(2)
(0)Scroll down for more posts ▼
